Safety study of a new medicine combination
This trial tests whether a new medicine (AG2304) is safe in healthy adults compared to taking two other medicines (AG23041 and AG23042) together. It aims to find out how the body handles the new medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 19 and 65 years old
- You are generally healthy (as determined by a doctor's exam and tests)
- You have not taken any experimental drug in the past 6 months
- You are willing to have your health monitored closely during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine in healthy people to see if it is safe and how the body handles it. Participating could help understand side effects before testing in patients.
This trial tests a new medicine called RO7806881 in healthy volunteers to see if it is safe, what dose is best, and how the body handles it. It is an early study that helps researchers decide if the drug should be tested in people with a disease.
This is an early-stage safety study testing a new experimental drug called REGN22044 in people with no serious health conditions. Researchers want to understand how safe the drug is, how well people tolerate it, and how the body processes it.
This trial tests how two study drugs, AD-2321 and AD-2322, interact with each other in the body and checks if they are safe for healthy adults. Taking part will help researchers learn more about these drugs for future use.
This trial tests a new drug called AD-123 and compares it to taking two other drugs (AD-1231 and AD-1232) together. It is for healthy adults to see how the body handles the drugs and if they are safe.
This trial tests how three study drugs interact with each other in healthy adults. It may help find safe doses for future treatments.
Hear when a new Pharmacokinetics trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.